Physician profile
Lori Lambert
NPI 1124026877
$6,054.67
in general payments reported to CMS, 2019-2025
37 companies · $456 in 2025
The $456 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $733 · 2021: $952 · 2022: $1,298 · 2023: $670 · 2024: $578 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.23 |
| Education | $191.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,745.67 | 2019-2023 | |
| Astellas Pharma US INC | $517.44 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $419.37 | 2019-2022 | |
| Bausch Health US, LLC | $273.51 | 2019-2023 | Aplenzin, Wellbutrin |
| Intra-Sana Laboratories | $263.32 | 2023-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Currax Pharmaceuticals LLC | $251.46 | 2020-2025 | Contrave |
| Myovant Sciences INC. | $232.20 | 2021-2022 | |
| Exeltis, USA INC. | $226.43 | 2019-2025 | Slynd |
| Millicent US INC | $215.99 | 2019-2025 | Femring, Intrarosa, Femlyv |
| Mayne Pharma Commercial LLC | $205.66 | 2021-2025 | |
| Novo Nordisk INC | $201.07 | 2020-2024 | Wegovy |
| Pfizer INC. | $175.16 | 2019-2024 | |
| Hologic Sales and Service, LLC | $166.31 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Amgen INC. | $137.98 | 2019-2020 | |
| Exact Sciences Corporation | $121.26 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $109.90 | 2019-2024 | |
| Mylan Pharmaceuticals INC. | $88.07 | 2019-2021 | |
| Organon LLC | $70.91 | 2021-2023 | Nexplanon |
| Biohaven Pharmaceutical Holding Company Ltd. | $70.14 | 2022 | |
| Avion Pharmaceuticals | $66.75 | 2019-2021 | |
| Coopersurgical, INC. | $51.20 | 2021-2025 | Paragard T 380a |
| Lilly USA, LLC | $49.35 | 2024-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $49.07 | 2019-2020 | |
| Nalpropion Pharmaceuticals LLC | $42.38 | 2019 | |
| Agile Therapeutics, INC. | $40.07 | 2021 | |
| Allergan, INC. | $39.77 | 2019-2020 | |
| Evofem Biosciences, INC. | $32.01 | 2022 | |
| Duchesnay USA Incorporated | $24.58 | 2019 | |
| Karl Storz Endoscopy-America | $23.64 | 2021 | |
| Glaxosmithkline, LLC. | $23.52 | 2020 | |
| Becton, Dickinson and Company | $18.39 | 2020 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Vivus LLC | $17.93 | 2019 | |
| Kaleo, INC. | $17.92 | 2019 | |
| Sumitomo Pharma America, INC. | $17.02 | 2023 | Myfembree |
| Mycovia Pharmaceuticals, INC. | $16.27 | 2022 | |
| Phadia US INC. | $14.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.